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2352-3964/Crown Copyright © 2016 Published by ElsevieGestational trophoblastic diseases (GTD) are a group of disorders
that originate from the trophoblast, which is the outer layer of the
blastocyst that normally gives rise to the placenta and is the ﬁrst tissue
to differentiate from the developing embryos after implantation. The
human chorionic gonadotropin (hCG) is one of the pregnancy
hormones and is secreted by trophoblastic cells. hCG is detected in
maternal blood seven days after fertilization (Cole, 2009) and is an
excellentmarker to detect chemical, normal and abnormal pregnancies.
GTD include pre-malignant stages, partial and complete
hydatidiform moles, and gestational trophoblastic neoplasia (GTN),
which encompass invasive mole, choriocarcinoma, placental site
trophoblastic tumor and epithelioid trophoblastic tumor, and are all
characterized by excessive proliferation of the trophoblast and
therefore excessive production of hCG. Among GTD, hydatidiform
mole is the most common. After initial diagnosis by ultrasound and
serum hCG quantitation, hydatidiformmoles are removed by dilatation
and curettage suction and the patients are followed-up with serial hCG
measurements until negativity or non-pregnant levels. Abnormal
decrease of hCG after curettage indicates risk of persistent trophoblastic
disease and malignant transformation into GTN (Fig. 1) that are classi-
ﬁed and treated according to the International Federation of Gynecolo-
gy and Obstetrics (FIGO) guidelines (FIGO Oncology Committee, 2002;
Seckl et al., 2010). The implementation of these guidelines has contrib-
uted to a better management of GTD and changed their outcomes from
nearly 100% fatality 60 years ago (Goldstein, 2012) to nearly 100% cure
rates in current clinical practice (Bolze et al., 2015). However, some pa-
tients still present with advanced or chemoresistant GTN. In addition,
hCG is a common tumor marker that is expressed by germ cell tumors
of the testis and the ovary and by 20–40% of common epithelial carcino-
ma such as bladder, cervix, lung, and naso-pharynx (Iles, 2007).Many of
these tumors are not 100% curable and those that express hCG have the
lowest survival rate.
In this issue of EBioMedicine, Openshaw et al. (2016) looked for
circulating free DNA (cfDNA) in the plasma of 18 women with post-
molar GTN, two with metastatic gestational choriocarcinoma, and ﬁvem.2015.12.022.
ter Research Institute, Glen site,
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r B.V. This is an open access article uwith hCG-secreting tumors of unknown origin. They isolated cfDNA
and used it in a multiplex assay that ampliﬁes 15 short tandem repeat
(STR) loci and the Amelogenin gender-determining marker to identify
whether the cfDNA contains circulating tumor DNA (ctDNA). By com-
paring the genotypes of cellular DNA of the patients and their partners
with those ampliﬁed from available preceding molar pregnancies and
cfDNA, they show the presence of paternal alleles in cfDNA in 13
patients, 12 with GTN and one with a tumor of unknown origin. The
amount of non-maternal ctDNA ranged from 9% to 55% of total cfDNA.
Multiplex STR genotyping on the tumor DNA is commonly used to de-
termine the parental contribution to molar pregnancies. It is also used
on choriocarcinoma tumor DNA to determine whether these tumors
have germ cell (e.g. ovarian origin) or gestational origin. The identiﬁca-
tion of paternal alleles is therefore a reliable and robust criterion to con-
ﬁrm the gestational origin of these tumors. This is particularly important
for the patients because the management and prognosis of gestational
and non-gestational hCG-secreting tumors are totally different
(Alifrangis et al., 2013).
The study by Openshaw and his colleagues demonstrated the
presence of circulating tumor DNA (ctDNA) in many patients with
GTN (60%) and will most likely open new testing opportunities aimed
at determining the origin of hCG-secreting tumors by genotyping
cfDNA. In post-molar GTN, the gestational origin of the tumor is usually
less questionable and such test may not be needed. However, genotyp-
ing cfDNA is important in patients when tumor sampling exposes the
patients to the risk of bleeding and tumor dissemination. Similarly,
when the preceding pregnancy is not a hydatidiform mole or/and
occurred several years ago, genotyping cfDNA offers a unique source
for determining the origin of the tumor and therefore adjust the FIGO
score to choose the best chemotherapy regimen. An illustration of the
importance of genotyping cfDNA is the case of patient CFD-023 whose
latest pregnancy was terminated 11 years ago.
In the study by Openshaw et al. (2016), a signiﬁcant correlation
between the amount of ctDNA and serum hCG was found in patients
with GTN and detectable ctDNA by genotyping. However, the exact re-
lationship between circulating tumor DNA and serum hCG remains to
be elucidated in future studies. Such studies may need to consider
some confounding factors such as the gestational stage of the pregnan-
cy, the time interval between the curettage and the diagnosis of GTN
and collection of blood to search for ctDNA; if accounted for, may help
reaching a better correlation. It would be also interesting to look fornder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Clinical management timeline of a patient with post-molar gestational trophoblastic neoplasia. A standard presentation of a patient with a clinical suspicion of hydatidiformmole
based high serum hCG and suggestive pelvic ultrasound. The patient underwent dilatation curettage and the diagnosis of hydatidiformmole was histologically conﬁrmed few days after
curettage. Serum hCGwasmonitoredweekly. According to FIGO guidelines, rising hCG indicated a post-molarmalignant transformation into GTN. After imaging and establishment of the
FIGO score, the patient was placed under single agent chemotherapy. Rising hCG despite 4 courses of single agent chemotherapy indicated monochemoresistance and the patient was
cured after 9 courses of polychemotherapy. hCG, stands for human chorionic gonadotropin; IU/L, international units per liter; HM, hydatidiform mole; GTN, gestational trophoblastic
neoplasia; FIGO, International Federation of Gynecology and Obstetrics.
12 P.-A. Bolze, R. Slim / EBioMedicine 4 (2016) 11–12correlation between the amounts of ctDNA and the risk of developing
post-molar GTN on blood samples drawn at the time of the curettage
of the moles and during the follow-up and treatments (Fig. 1). Further-
more, to better understand the diagnostic value of ctDNA, it is important
to know the cellular origin of the DNA that is shed in thematernal circu-
lation. In pre-eclampsia and intra-uterine growth restriction, the
amounts of circulating fetal DNA correlate with placental apoptosis
and necrosis rather than with placental volume (Taglauer et al., 2014).
In GTDs, apoptotic cells are found at higher amounts in hydatidiform
moles that regress spontaneously than in moles that give rise to GTNs
(Chiu et al., 2001). Therefore, even if all confounding factors are taken
into consideration, it is possible that the amounts of ctDNAmaynot cor-
relate positively with the amounts of serum hCG in all patients.
In conclusion, the present study opens interesting new perspectives
to better understand the pathophysiology of GTN and provides hope for
a reliable diagnostic approach from a simple blood sample to improve
the management of patients with hCG-secreting tumors of unknown
origin.
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